Akebia Therapeutics Inc (NASDAQ:AKBA) – Equities researchers at Piper Jaffray Companies reduced their FY2019 EPS estimates for shares of Akebia Therapeutics in a research report issued on Tuesday, November 12th. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will earn ($1.70) per share for the year, down from their prior forecast of ($1.26). Piper Jaffray Companies also issued estimates for Akebia Therapeutics’ Q4 2019 earnings at ($0.50) EPS, Q1 2020 earnings at ($0.27) EPS, Q2 2020 earnings at ($0.49) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.15) EPS, FY2020 earnings at ($1.18) EPS, Q1 2021 earnings at ($0.41) EPS, Q2 2021 earnings at ($0.40) EPS, Q3 2021 earnings at ($0.38) EPS, FY2021 earnings at ($1.48) EPS, FY2022 earnings at $0.46 EPS and FY2023 earnings at $1.42 EPS.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.09). The business had revenue of $91.98 million for the quarter, compared to the consensus estimate of $93.94 million. Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%.

A number of other research analysts also recently weighed in on AKBA. BidaskClub downgraded Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 1st. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Needham & Company LLC lowered their price target on Akebia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Mizuho set a $16.00 price target on Akebia Therapeutics and gave the company a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Akebia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $12.88.

Shares of Akebia Therapeutics stock opened at $3.36 on Friday. Akebia Therapeutics has a 1-year low of $2.99 and a 1-year high of $10.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.34 and a quick ratio of 1.05. The company has a market capitalization of $383.00 million, a P/E ratio of -1.38 and a beta of 1.51. The business’s fifty day moving average price is $4.00 and its two-hundred day moving average price is $4.47.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio grew its stake in Akebia Therapeutics by 6.0% in the second quarter. Strs Ohio now owns 47,800 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 2,700 shares in the last quarter. M&T Bank Corp grew its stake in Akebia Therapeutics by 24.9% in the second quarter. M&T Bank Corp now owns 14,507 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 2,894 shares in the last quarter. Sun Life Financial INC grew its stake in Akebia Therapeutics by 9.3% in the second quarter. Sun Life Financial INC now owns 34,162 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 2,907 shares in the last quarter. Aperio Group LLC purchased a new position in Akebia Therapeutics in the second quarter valued at about $31,000. Finally, Tower Research Capital LLC TRC purchased a new position in Akebia Therapeutics in the third quarter valued at about $30,000. Hedge funds and other institutional investors own 71.91% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

See Also: Profit margin is different from the revenue

Earnings History and Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.